{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:41:53Z","timestamp":1790102513017,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"EHDEN","award":["806968"],"award-info":[{"award-number":["806968"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40264-024-01478-6","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T06:02:30Z","timestamp":1727157750000},"page":"59-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Disproportionality Analysis and Characterisation of Medication Errors in EudraVigilance: Exploring Findings on Sexes and Age Groups"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0786-4712","authenticated-orcid":false,"given":"Victor","family":"Pera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-026X","authenticated-orcid":false,"given":"Jan A.","family":"Kors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-9386","authenticated-orcid":false,"given":"Erik M.","family":"van Mulligen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0621-1979","authenticated-orcid":false,"given":"Peter R.","family":"Rijnbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-4904","authenticated-orcid":false,"given":"Katia M. C.","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"1478_CR1","unstructured":"EMA. Medication errors 2021. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/medication-errors. Accessed 2 Sep 2024."},{"key":"1478_CR2","doi-asserted-by":"publisher","unstructured":"Pera V, van Vaerenbergh F, Kors JA, van Mulligen EM, Parry R, de Wilde M, et al. Descriptive analysis on disproportionate medication errors and associated patient characteristics in the Food and Drug Administration\u2019s Adverse Event Reporting System. Pharmacoepidemiol Drug Saf. https:\/\/doi.org\/10.1002\/pds.5743.","DOI":"10.1002\/pds.5743"},{"key":"1478_CR3","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40264-017-0569-3","volume":"40","author":"V Newbould","year":"2017","unstructured":"Newbould V, Le Meur S, Goedecke T, Kurz X. Medication errors: a characterisation of spontaneously reported cases in EudraVigilance. Drug Saf. 2017;40:1241\u20138. https:\/\/doi.org\/10.1007\/s40264-017-0569-3.","journal-title":"Drug Saf"},{"key":"1478_CR4","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.sapharm.2019.10.003","volume":"16","author":"N Mirosevic Skvrce","year":"2020","unstructured":"Mirosevic Skvrce N, Galic I, Pacadi C, Kandzija N, Mucalo I. Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation. Res Soc Admin Pharm. 2020;16:928\u201334. https:\/\/doi.org\/10.1016\/j.sapharm.2019.10.003.","journal-title":"Res Soc Admin Pharm."},{"key":"1478_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019101","volume":"8","author":"GA Assiri","year":"2018","unstructured":"Assiri GA, Shebl NA, Mahmoud MA, Aloudah N, Grant E, Aljadhey H, et al. What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature. BMJ Open. 2018;8: e019101. https:\/\/doi.org\/10.1136\/bmjopen-2017-019101.","journal-title":"BMJ Open"},{"key":"1478_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.2146\/ajhp070190","volume":"64","author":"DW Bates","year":"2007","unstructured":"Bates DW. Preventing medication errors: a summary. Am J Health Syst Pharm. 2007;64:S3-9. https:\/\/doi.org\/10.2146\/ajhp070190.","journal-title":"Am J Health Syst Pharm"},{"key":"1478_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-016-0410-4","volume":"39","author":"T Goedecke","year":"2016","unstructured":"Goedecke T, Ord K, Newbould V, Brosch S, Arlett P. Medication errors: new EU good practice guide on risk minimisation and error prevention. Drug Saf. 2016;39:491\u2013500. https:\/\/doi.org\/10.1007\/s40264-016-0410-4.","journal-title":"Drug Saf"},{"key":"1478_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/medicines8090046","volume":"8","author":"AA Mutair","year":"2021","unstructured":"Mutair AA, Alhumaid S, Shamsan A, Zaidi ARZ, Mohaini MA, Al Mutairi A, et al. The effective strategies to avoid medication errors and improving reporting systems. Medicines (Basel). 2021;8:46. https:\/\/doi.org\/10.3390\/medicines8090046.","journal-title":"Medicines (Basel)."},{"key":"1478_CR9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1186\/s12913-022-08864-9","volume":"22","author":"SS Tabatabaee","year":"2022","unstructured":"Tabatabaee SS, Ghavami V, Javan-Noughabi J, Kakemam E. Occurrence and types of medication error and its associated factors in a reference teaching hospital in northeastern Iran: a retrospective study of medical records. BMC Health Serv Res. 2022;22:1420. https:\/\/doi.org\/10.1186\/s12913-022-08864-9.","journal-title":"BMC Health Serv Res"},{"key":"1478_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/nursrep12040098","volume":"12","author":"A Alandajani","year":"2022","unstructured":"Alandajani A, Khalid B, Ng YG, Banakhar M. Knowledge and attitudes regarding medication errors among nurses: a cross-sectional study in major Jeddah hospitals. Nurs Rep. 2022;12:1023\u201339. https:\/\/doi.org\/10.3390\/nursrep12040098.","journal-title":"Nurs Rep."},{"key":"1478_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066531","volume":"12","author":"T Mohammed","year":"2022","unstructured":"Mohammed T, Mahmud S, Gintamo B, Mekuria ZN, Gizaw Z. Medication administration errors and associated factors among nurses in Addis Ababa federal hospitals, Ethiopia: a hospital-based cross-sectional study. BMJ Open. 2022;12: e066531. https:\/\/doi.org\/10.1136\/bmjopen-2022-066531.","journal-title":"BMJ Open"},{"key":"1478_CR12","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1136\/ejhpharm-2020-002298","volume":"28","author":"A Mulac","year":"2021","unstructured":"Mulac A, Taxis K, Hagesaether E, Granas AG. Severe and fatal medication errors in hospitals: findings from the Norwegian Incident Reporting System. Eur J Hosp Pharm. 2021;28:e56-61. https:\/\/doi.org\/10.1136\/ejhpharm-2020-002298.","journal-title":"Eur J Hosp Pharm"},{"key":"1478_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/PTS.0b013e3181dcae06","volume":"6","author":"TK Gandhi","year":"2010","unstructured":"Gandhi TK, Seger AC, Overhage JM, Murray MD, Hope C, Fiskio J, et al. Outpatient adverse drug events identified by screening electronic health records. J Patient Saf. 2010;6:91. https:\/\/doi.org\/10.1097\/PTS.0b013e3181dcae06.","journal-title":"J Patient Saf"},{"key":"1478_CR14","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1016\/j.vaccine.2012.04.014","volume":"30","author":"OQB Al-lela","year":"2012","unstructured":"Al-lela OQB, Bahari MB, Al-abbassi MG, Salih MRM, Basher AY. Estimation of immunization providers\u2019 activities cost, medication cost, and immunization dose errors cost in Iraq. Vaccine. 2012;30:3862\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2012.04.014.","journal-title":"Vaccine"},{"key":"1478_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/pds.4188","volume":"26","author":"EK Walsh","year":"2017","unstructured":"Walsh EK, Hansen CR, Sahm LJ, Kearney PM, Doherty E, Bradley CP. Economic impact of medication error: a systematic review. Pharmacoepidemiol Drug Saf. 2017;26:481\u201397. https:\/\/doi.org\/10.1002\/pds.4188.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1478_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40264-019-00850-1","volume":"42","author":"PJ Gates","year":"2019","unstructured":"Gates PJ, Baysari MT, Gazarian M, Raban MZ, Meyerson S, Westbrook JI. Prevalence of medication errors among paediatric inpatients: systematic review and meta-analysis. Drug Saf. 2019;42:1329\u201342. https:\/\/doi.org\/10.1007\/s40264-019-00850-1.","journal-title":"Drug Saf"},{"key":"1478_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.farma.2023.03.006","volume":"47","author":"G-C Beatriz","year":"2023","unstructured":"Beatriz G-C, Mar\u00eda Jos\u00e9 O, In\u00e9s J-L, Yolanda H-G, Concha \u00c1-D-V, Javier T-S, et al. Medication errors in children visiting pediatric emergency departments. Farm Hosp. 2023;47:141\u20137. https:\/\/doi.org\/10.1016\/j.farma.2023.03.006.","journal-title":"Farm Hosp"},{"key":"1478_CR18","unstructured":"EMA. EudraVigilance. 2018. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance. Accessed 15 Aug 2023."},{"key":"1478_CR19","unstructured":"EMA. EudraVigilance: electronic reporting. 2018. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/eudravigilance-electronic-reporting. Accessed 15 Aug 2023."},{"key":"1478_CR20","unstructured":"EMA. Access to EudraVigilance data. 2018. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/access-eudravigilance-data. Accessed 15 Aug 2023."},{"key":"1478_CR21","unstructured":"European database of suspected adverse drug reaction reports. Available from: https:\/\/www.adrreports.eu\/. Accessed 15 Aug 2023."},{"key":"1478_CR22","unstructured":"1.4.1 Narrow and Broad Scope Introductory. Guide for Standardised MedDRA Queries (SMQs) Version 24.1. 2021. https:\/\/www.meddra.org\/how-to-use\/supportdocumentation\/english. Accessed 4 Jan 2024."},{"key":"1478_CR23","unstructured":"Parry R. AIOLI. Available from: https:\/\/github.com\/mi-erasmusmc\/aioli 2021. Accessed 2 Sep 2024."},{"key":"1478_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3: 160026. https:\/\/doi.org\/10.1038\/sdata.2016.26.","journal-title":"Sci Data"},{"key":"1478_CR25","unstructured":"Anatomical Therapeutic Chemical (ATC) Classification. Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification. Accessed 11 Apr 2024."},{"key":"1478_CR26","unstructured":"Parry R. AEOLUS. 2021. Available from: https:\/\/github.com\/mi-erasmusmc\/faersdbstats. Accessed 2 Sep 2024."},{"key":"1478_CR27","unstructured":"European Medicines Agency. Screening for adverse reactions in EudraVigilance. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactionseudravigilance_en.pdf. Accessed 8 July 2021."},{"key":"1478_CR28","unstructured":"European Medicines Agency. EudraVigilance User Manual. Marketing Authorisation Holders - EudraVigilance access via the EudraVigilance Data Analysis System, version 2.1. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/eudravigilanceuser-manual-marketing-authorisation-holders_en.pdf. Accessed 21 Sept 2023."},{"key":"1478_CR29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1163\/ej.9789004163300.i-1081.897","volume-title":"Handbook of transnational economic governance regimes","author":"J Abraham","year":"2010","unstructured":"Abraham J. International Conference On Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. In: Tietje C, Brouder A, editors. Handbook of transnational economic governance regimes. Leiden: Brill Nijhoff; 2010. p. 1041\u201353. https:\/\/doi.org\/10.1163\/ej.9789004163300.i-1081.897."},{"key":"1478_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nmeth.1902","volume":"9","author":"N Gehlenborg","year":"2012","unstructured":"Gehlenborg N, Wong B. Heat maps. Nat Methods. 2012;9:213. https:\/\/doi.org\/10.1038\/nmeth.1902.","journal-title":"Nat Methods"},{"key":"1478_CR31","doi-asserted-by":"publisher","unstructured":"Wei W, Chen L, Zhou H, Liu J, Zhang Y, Feng S, et al. Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system. Front Pharmacol. 2023;14:1208456. https:\/\/doi.org\/10.3389\/fphar.2023.1208456.","DOI":"10.3389\/fphar.2023.1208456"},{"key":"1478_CR32","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/bioinformatics\/btx657","volume":"34","author":"T Galili","year":"2018","unstructured":"Galili T, O\u2019Callaghan A, Sidi J, Sievert C. heatmaply: an R package for creating interactive cluster heatmaps for online publishing. Bioinformatics. 2018;34:1600\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btx657.","journal-title":"Bioinformatics"},{"key":"1478_CR33","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/jep.13668","volume":"28","author":"N Alqahtani","year":"2022","unstructured":"Alqahtani N. Reducing potential errors associated with insulin administration: an integrative review. J Eval Clin Pract. 2022;28:1037\u201349. https:\/\/doi.org\/10.1111\/jep.13668.","journal-title":"J Eval Clin Pract"},{"key":"1478_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00228-021-03212-y","volume":"78","author":"A Al Rowily","year":"2022","unstructured":"Al Rowily A, Jalal Z, Price MJ, Abutaleb MH, Almodiaemgh H, Al Ammari M, et al. Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78:623\u201345. https:\/\/doi.org\/10.1007\/s00228-021-03212-y.","journal-title":"Eur J Clin Pharmacol"},{"key":"1478_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5055\/jom.2007.0004","volume":"3","author":"SM Dy","year":"2007","unstructured":"Dy SM, Shore AD, Hicks RW, Morlock LL. Medication errors with opioids: results from a national reporting system. J Opioid Manag. 2007;3:189\u201394. https:\/\/doi.org\/10.5055\/jom.2007.0004.","journal-title":"J Opioid Manag"},{"key":"1478_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1155\/2011\/739359","volume":"16","author":"DC Mc","year":"2011","unstructured":"Mc DC. Opioid medication errors in pediatric practice: four years\u2019 experience of voluntary safety reporting. Pain Res Manag. 2011;16:93\u20138.","journal-title":"Pain Res Manag"},{"key":"1478_CR37","doi-asserted-by":"publisher","first-page":"205031211877795","DOI":"10.1177\/2050312118777953","volume":"6","author":"Y Motooka","year":"2018","unstructured":"Motooka Y, Matsui T, Slaton RM, Umetsu R, Fukuda A, Naganuma M, et al. Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004\u20132016. SAGE Open Med. 2018;6:2050312118777953. https:\/\/doi.org\/10.1177\/2050312118777953.","journal-title":"SAGE Open Med."},{"key":"1478_CR38","first-page":"729","volume":"63","author":"CM Hales","year":"2014","unstructured":"Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729\u201331.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1478_CR39","unstructured":"Varicella zoster virus vaccines: medication errors. Available from: https:\/\/www.medsafe.govt.nz\/profs\/PUArticles\/Sep2015\/VaricellaVaccines.htm. Accessed 28 Sep 2023."},{"key":"1478_CR40","unstructured":"United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC)\/Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990 - 09\/15\/2023, CDC WONDER on-line database. Available from: http:\/\/wonder.cdc.gov\/vaers.html. Accessed 29 Sep 2023."},{"key":"1478_CR41","doi-asserted-by":"publisher","unstructured":"Shimabukuro TT, Miller ER, Strikas RA, Hibbs BF, Dooling K, Goud R, et al. Notes from the Field: Vaccine Administration Errors Involving Recombinant Zoster Vaccine \u2014 United States, 2017\u20132018. MMWR Morb Mortal Wkly Rep. 2018;67:585\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm6720a4.","DOI":"10.15585\/mmwr.mm6720a4"},{"key":"1478_CR42","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1080\/21645515.2018.1456598","volume":"14","author":"ER Miller","year":"2018","unstructured":"Miller ER, Lewis P, Shimabukuro TT, Su J, Moro P, Woo EJ, et al. Post-licensure safety surveillance of zoster vaccine live (Zostavax\u00ae) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006\u20132015. Hum Vaccin Immunother. 2018;14:1963\u20139. https:\/\/doi.org\/10.1080\/21645515.2018.1456598.","journal-title":"Hum Vaccin Immunother"},{"key":"1478_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/picr.PICR_140_18","volume":"11","author":"R Neha","year":"2020","unstructured":"Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006\u20132017. Perspect Clin Res. 2020;11:24\u201330. https:\/\/doi.org\/10.4103\/picr.PICR_140_18.","journal-title":"Perspect Clin Res"},{"key":"1478_CR44","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.vaccine.2020.11.026","volume":"39","author":"P Haber","year":"2021","unstructured":"Haber P, Tate J, Marquez PL, Moro PL, Parashar U. Safety profile of rotavirus vaccines among individuals aged \u22658 months of age, United States, vaccine adverse event reporting system (VAERS), 2006\u20132019. Vaccine. 2021;39:746\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.026.","journal-title":"Vaccine"},{"key":"1478_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/15563650.2018.1523424","volume":"57","author":"T Vial","year":"2019","unstructured":"Vial T, Patat A-M, Paret N, Boels D, Torrents R, Nisse P, et al. Risperidone medication errors in children: an analysis of French poison centres data. Clin Toxicol. 2019;57:362\u20137. https:\/\/doi.org\/10.1080\/15563650.2018.1523424.","journal-title":"Clin Toxicol"},{"key":"1478_CR46","volume-title":"Risperidone","author":"SE McNeil","year":"2023","unstructured":"McNeil SE, Gibbons JR, Cogburn M. Risperidone. Treasure Island: StatPearls Publishing; 2023."},{"key":"1478_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonz\u00e1lez-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11\u201334. https:\/\/doi.org\/10.1080\/14740338.2016.1240783.","journal-title":"Expert Opin Drug Saf"},{"key":"1478_CR48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/rheumatology\/key207","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis: executive summary. Rheumatology. 2019;58:220\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/key207.","journal-title":"Rheumatology"},{"key":"1478_CR49","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.3390\/jcm11112955","volume":"11","author":"M Bellan","year":"2022","unstructured":"Bellan M, Scotti L, Ferrante D, Calzaducca E, Manfredi GF, Sainaghi PP, et al. Risk of severe infection among rheumatoid arthritis patients on biological DMARDs: a population-based cohort study. J Clin Med. 2022;11:2955. https:\/\/doi.org\/10.3390\/jcm11112955.","journal-title":"J Clin Med"},{"key":"1478_CR50","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.4103\/jfmpc.jfmpc_2147_21","volume":"11","author":"P Gupta","year":"2022","unstructured":"Gupta P, Padhan P, Bhargava N, Behera PK, Tripathy KP, Panda SS. Spectrum of infections occurring in patients of autoimmune rheumatic diseases on treatment with biological versus conventional disease-modifying antirheumatic drugs: a comparative study. J Family Med Prim Care. 2022;11:3575\u201383. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2147_21.","journal-title":"J Family Med Prim Care."},{"key":"1478_CR51","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St. Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1478_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"J-L Faillie","year":"2019","unstructured":"Faillie J-L. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74:225\u201332. https:\/\/doi.org\/10.1016\/j.therap.2019.01.006.","journal-title":"Therapie"},{"key":"1478_CR53","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf. 2006;29:385\u201396. https:\/\/doi.org\/10.2165\/00002018-200629050-00003.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01478-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01478-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01478-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:23:43Z","timestamp":1736335423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01478-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1478"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01478-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"14 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work has received support from the European Health Data & Evidence Network (EHDEN) project. EHDEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 806968.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The research group from the Department of Medical Informatics received unconditional research grants from Chiesi, UCB, Amgen, Johnson and Johnson, and the European Medicines Agency, none of which relates to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"An agreement has been made with the EMA not to transfer or dispose of the ICSR data set Level 2A for which access is provided under the condition of the Confidentiality Undertaking to any third party. It is agreed not to permit any third party to access, study, analyse, refer to or otherwise use the data or permit any party to reproduce any ICSR data. A publicly available version of this database is available here: . Further inquiries can be directed to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"VP: conceptualisation, formal analysis, visualisation, writing (original draft), writing (review and editing), methodology, visualisation. JK: software, writing (review and editing). EV: software, writing (review and editing). MdW: software, writing (review and editing). PR: supervision, writing (review and editing). KV: conceptualisation, supervision, writing (review and editing).\u00a0All authors read and approved the final version.\u00a0","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}